Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, PDT, FVT

OneOme Launches Upgrades to RightMed® Pharmacogenomic Solution



MINNEAPOLIS, Oct. 5, 2017 /PRNewswire/ -- OneOme today launched several significant upgrades to its RightMed® pharmacogenomics solution. The RightMed solution now includes an additional gene (SLC6A4), a streamlined psychiatry report, a secure tool for patients to share their results with other providers, and insurance billing. The upgrades expand the utility of OneOme's RightMed comprehensive test and supporting products.

OneOme's pioneering RightMed® test and interactive technology help to combat adverse drug reactions and improve health outcomes and patient safety. (PRNewsfoto/OneOme)

"Upgrading the RightMed solution means OneOme is able to provide even more powerful tools for integrating pharmacogenomics into clinical practice," Paul Owen, CEO of OneOme, said. "Our team is proud to provide these additional tools to help providers easily interpret RightMed test results and to allow patients to seek reimbursement from their health insurance. With these upgrades, OneOme continues our mission of providing scientifically sound, cost-effective pharmacogenomic testing and tools for patients and providers across the globe."

OneOme uses the power of DNA to predict which medications may or may not work best for an individual patient. The goal is to personalize medications to improve patient health by increasing drug effectiveness, as well as decreasing side effects, adverse drug reactions, and unintended interactions with other medications. The RightMed solution better enables providers to more effectively treat conditions in primary care and a variety of specialty areas including mental health, oncology, cardiology, pain, and more.

OneOme is introducing an optional specialty report initially focused on mental health to aid clinicians in prescribing psychiatric medications. In addition to the standard RightMed comprehensive test report which covers 30 medical indications and 340+ drugs, providers can now add a complimentary psychiatry report. The psychiatry report contains a subset of medications selected and classified by OneOme for a more streamlined view into how a patient may respond to medications used to treat mental health conditions, including anxiety, depression, schizophrenia, and bipolar disorder.

OneOme is committed to analyzing genes supported by scientific evidence that meets its rigorous criteria for inclusion. To that end, OneOme has added an additional gene to the RightMed comprehensive test that will further assist patients facing mental health challenges. The gene SLC6A4, a serotonin transporter, has been added to the RightMed test to provide additional genetic information to inform a provider on how a patient may respond to certain antidepressants.

Finally, OneOme is continuing its work to integrate its cost-effective testing into regular clinical practice. To support this, OneOme now offers the option of billing a patient's health insurance company for the cost of the RightMed comprehensive test. OneOme is also providing additional functionality for patients to share their test results with all of their medical providers through a secure patient portal. Since a patient's DNA doesn't change, results from a pharmacogenomic test can be used many times over the course of a patient's life. Allowing providers to bill a patient's insurance and making it easier for patients to share their results furthers OneOme's goal of bringing the power of pharmacogenomics into routine clinical care.

Anyone can take the RightMed test, although patients who may benefit most include: those who are taking certain classes of medication, such as psychiatric, cardiology or pain medications; those undergoing cancer treatments; those who are struggling with adverse drug reactions or medications that are not working; or those who are on multiple medications.

OneOme is hosting a webinar on October 17 at 11:30 a.m. CDT for medical providers and those interested to learn more about the new psychiatry report and the SLC6A4 gene. Learn more and register here.

About OneOme      
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com

Editor's Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.

Laura Smith
(612) 455-2369
Laura.Smith@russellherder.com

 

SOURCE OneOme


These press releases may also interest you

at 14:20
March of Dimes released the following statement from President Stacey D. Stewart on the Notice of Proposed Rulemaking issued by the Administration yesterday expanding the circumstances under which immigrants could be considered a "public charge,"...

at 13:20
Abbott today announced positive clinical study results from a randomized controlled trial comparing treatment with the MitraClip® device to guideline-directed medical therapy in select patients with secondary (or functional) mitral regurgitation, or...

at 12:00
SAN FRANCISCO, Sept. 23, 2018 /PRNewswire-PRWeb/ -- Exposure to Tickborne Relapsing Fever is widespread in California according to a study published in the prestigious International Journal of General Medicine (https://bit.ly/2prCQWv). The report...

at 11:33
The Green Beret Foundation, an organization dedicated to helping soldiers of the U.S. Army Special Forces and their families, announced today that Executive Director Jennifer Paquette and Director of Finance Melissa Pucino have resigned from their...

at 11:00
LEXINGTON, Mass., Sept. 23, 2018 /PRNewswire-PRWeb/ -- Ninestone Corporation, a management consulting firm that specializes in working with healthcare, small business and non-profit organizations, announced today their selection as an approved vendor...

at 10:28
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of AbbVie Inc. ("AbbVie" or the "Company")  between...




News published on 5 october 2017 at 11:11 and distributed by: